Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Lamotrigine
Lexon Pharmaceuticals (Ireland) Limited
N03AX; N03AX09
Lamotrigine
200 milligram(s)
Chewable/dispersible tablet
Other antiepileptics; lamotrigine
2017-03-31
* IF YOU EXPERIENCE A RASH OR SUNBURN AFTER TAKING LAMOTRIGINE AND HAVING BEEN EXPOSED TO SUN OR ARTIFICIAL LIGHT (E.G. SOLARIUM). Your doctor will check your treatment and may advise you to avoid sunlight or protect yourself against the sun (e.g. use of a sunscreen and/or to wear protective clothing) * IF YOU HAVE EVER DEVELOPED MENINGITIS AFTER TAKING LAMOTRIGINE (_read _ _ the description of these symptoms in Section 4 of this leaflet: Rare side _ _ effects_) * IF YOU ARE ALREADY TAKING MEDICINE THAT CONTAINS LAMOTRIGINE. * IF YOU HAVE A CONDITION CALLED BRUGADA SYNDROME, OR OTHER HEART PROBLEMS. Brugada syndrome is a genetic disease that results in abnormal electrical activity within the heart. ECG abnormalities which may lead to arrhythmias (abnormal heart rhythm) can be triggered by lamotrigine. If any of these applies to you: TELL YOUR DOCTOR, who may decide to lower the dose, or that Lamictal is not suitable for you. IMPORTANT INFORMATION ABOUT POTENTIALLY LIFE-THREATENING REACTIONS A small number of people taking Lamictal get an allergic reaction or potentially life-threatening skin reaction, which may develop into more serious problems if they are not treated. These can include Stevens - Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). You need to know the symptoms to look out for while you are taking Lamictal. READ THE DESCRIPTION OF THESE SYMPTOMS IN SECTION 4 OF THIS LEAFLET under ‘_Potentially life-threatening reactions: get a doctor’s help _ _straight away’_. HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)_ _ There have been reports of a rare but very serious immune system reaction, in patients taking lamotrigine. CONTACT YOUR DOCTOR OR PHARMACIST IMMEDIATELY if you experience any of the following symptoms while taking lamotrigine: fever, rash, neurological symptoms (e.g. shaking or tremor, confusional state, disturbances of brain function)._ _ _ _ THOUGHTS OF HARMING YOURSELF OR SUICIDE Anti-epileptic medicines are used to Read the complete document
Health Products Regulatory Authority 10 February 2022 CRN00CSP3 Page 1 of 2 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lamictal 200 mg chewable/dispersible tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each Lamictal 200 mg chewable/dispersible tablet contains 200 mg lamotrigine. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Chewable/dispersible tablet. _Product imported from Germany_ White to off-white multi-faceted, super-elliptical, tablets of 10.4 mm with a blackcurrant odour, marked GSEC5 on one side and 200 on the other. The tablets may be slightly mottled. 4 CLINICAL PARTICULARS As per PA1077/061/010 5 PHARMACOLOGICAL PROPERTIES As per PA1077/061/010 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS Calcium carbonate Hydroxypropyl cellulose Aluminium magnesium silicate Sodium starch glycolate Povidone K30 Sodium saccharine Magnesium stearate (Ph.Eur) Blackcurrant flavour. 6.2 INCOMPATIBILITIES Not applicable. 6.3 SHELF LIFE The shelf life expiry date for this product shall be the date shown on the blister and outer package of the product on the market in the country of origin. 6.4 SPECIAL PRECAUTIONS FOR STORAGE This medicinal product does not require any special storage conditions. 6.5 NATURE AND CONTENTS OF CONTAINER Health Products Regulatory Authority 10 February 2022 CRN00CSP3 Page 2 of 2 Blister packs of 56 tablets. 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL No special requirements. 7 PARALLEL PRODUCT AUTHORISATION HOLDER Lexon Pharmaceuticals (Ireland) Limited Block 3 Harcourt Centre Harcourt Road Dublin 2 Ireland 8 PARALLEL PRODUCT AUTHORISATION NUMBER PPA23176/003/006 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 31 st March 2017 10 DATE OF REVISION OF THE TEXT October 2021 Read the complete document